IJMDC

Article Text
Article Info
Citation Tools
Article Metrics
Permissions

Review Article

IJMDC. 2023; 7(4): 687-694

β-blocker dose, heart rate reduction, and death in patients with heart f ailure: a systematic review

Authors: Maram Alomari, Abdullah Alyahia, Nuha Al Otaibi, Naif Al Ruais, Norah Alzayed, Dhaifallah Alotaibi.

ABSTRACT

Background: In individuals with systolic chronic Heart failure (HF), β-blockers enhance cardiac function and increase survival. The precise processes driving these advantages are unclear, though. It is uncertain if there is a direct link between clinical results with these medications and heart rate (HR) decrease. According to recommendations, β-blockers should be administered to individuals with HF at effective dosages in clinical studies. It is unknown if the advantages of β-blockade are dose-related, even though the disadvantages are. Aim: To investigate the survival benefits of β-blockade in HF and its association with the level of HR reduction or the β-blocker dose. Methods: This is an updated systematic review of studies discussing the survival benefits of β-blockade in HF and its association with the level of HR reduction or the β-blocker dose between 2020 and 2022. The PubMed and Google Scholar databases were used to explore studies regarding our subject. The keywords included “β-blocker Dose, Heart Rate Reduction, Death, Patients, and Heart Failure,” and were used in various combinations. The inclusion criteria were original studies that reported the survival benefits of β-blockade in HF and its association with the level of HR reduction or the β-blocker dose and full-text articles. Results: Though 240 articles were obtained, only 8 of them met the inclusion criteria. The studies included more than 120,348 patients: 4 prospective studies, 1 case series, 1 multicenter, a randomized clinical trial, and 2 observational cohort studies. Conclusion: Oral β-blocker therapy was independently associated with a lower risk of poor in-hospital outcomes in sore throat speech therapy (ST)-elevation myocardial infarction patients with Killip class II or III HF. In individuals with chronic or acute coronary syndrome, an HR of 70 bpm was related to poorer clinical indicators and prognosis. β-blocker therapy was independently associated with a lower risk of all-cause death. In HF patients with reduced ejection fraction with advanced chronic kidney disease, using β-blockers was linked to decreased morbidity and death rates. Moreover, HF patients who receive medical treatment with βb can reverse exercise oscillatory ventilation.

Keywords:
β-blocker dose, heart rate reduction, death, patients, and heart failure.

View PDF

β-blocker dose, heart rate reduction, and death in patients with heart f ailure: a systematic review

Authors
Maram Alomari
Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
PubMed articles Google scholar articles

Abdullah Alyahia
Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
PubMed articles Google scholar articles

Nuha Al Otaibi
Prince Sultan Military Medical City, Riyadh, Saudi Arabia
PubMed articles Google scholar articles

Naif Al Ruais
MOH, Saudi Arabia
PubMed articles Google scholar articles

Norah Alzayed
Prince Sultan Military Medical City, Riyadh, Saudi Arabia
PubMed articles Google scholar articles

Dhaifallah Alotaibi
Prince Sultan Cardiac Center, Riyadh, Saudi Arabia.
PubMed articles Google scholar articles

Correspondence to:
. Maram Alomari, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia.; ph.d.maram@hotmail.com

Publication history
Received 06 Nov 2022
Accepted 30 Dec 2022
Published online 12 Jan 2023
Published in print 15 Jan 2023

How to cite this article?

Export to EndNote Export to refMan

Pubmed Style

Alomari M, Alyahia A, Otaibi NA, Ruais NA, Alzayed N, Alotaibi D. β-blocker dose, heart rate reduction, and death in patients with heart f ailure: a systematic review. IJMDC. 2023; 7(4): 687-694. doi:10.24911/IJMDC.51-1667765600

Web Style

Alomari M, Alyahia A, Otaibi NA, Ruais NA, Alzayed N, Alotaibi D. β-blocker dose, heart rate reduction, and death in patients with heart f ailure: a systematic review. https://www.ijmdc.com/?mno=127902 [Access: March 22, 2023]. doi:10.24911/IJMDC.51-1667765600

AMA (American Medical Association) Style

Vancouver/ICMJE Style

Alomari M, Alyahia A, Otaibi NA, Ruais NA, Alzayed N, Alotaibi D. β-blocker dose, heart rate reduction, and death in patients with heart f ailure: a systematic review. IJMDC. (2023), [cited March 22, 2023]; 7(4): 687-694. doi:10.24911/IJMDC.51-1667765600

Harvard Style

Alomari, M., Alyahia, . A., Otaibi, . N. A., Ruais, . N. A., Alzayed, . N. & Alotaibi, . D. (2023) β-blocker dose, heart rate reduction, and death in patients with heart f ailure: a systematic review. IJMDC, 7 (4), 687-694. doi:10.24911/IJMDC.51-1667765600

Turabian Style

Alomari, Maram, Abdullah Alyahia, Nuha Al Otaibi, Naif Al Ruais, Norah Alzayed, and Dhaifallah Alotaibi. 2023. β-blocker dose, heart rate reduction, and death in patients with heart f ailure: a systematic review. International Journal of Medicine in Developing Countries, 7 (4), 687-694. doi:10.24911/IJMDC.51-1667765600

Chicago Style

Alomari, Maram, Abdullah Alyahia, Nuha Al Otaibi, Naif Al Ruais, Norah Alzayed, and Dhaifallah Alotaibi. "β-blocker dose, heart rate reduction, and death in patients with heart f ailure: a systematic review." International Journal of Medicine in Developing Countries 7 (2023), 687-694. doi:10.24911/IJMDC.51-1667765600

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Alomari, M., Alyahia, . A., Otaibi, . N. A., Ruais, . N. A., Alzayed, . N. & Alotaibi, . D. (2023) β-blocker dose, heart rate reduction, and death in patients with heart f ailure: a systematic review. International Journal of Medicine in Developing Countries, 7 (4), 687-694. doi:10.24911/IJMDC.51-1667765600

Article Statistics

Request permissions

If you wish to reuse any part or all of this article please contact the copyright holder, contact@ijmdc.com.

International Journal of Medicine in Developing Countries